摘要
抗血管内皮生长因子(VEGF)药物属生物制剂,是任何含有生物技术衍生蛋白质作为活性物质的医药产品。随着抗VEGF药物研究的不断深入,其在打破疾病的病理生理过程,从而进一步抑制疾病的进展方面取得显著疗效。目前,抗VEGF药物已成为治疗眼部许多视网膜疾病的主要手段,但在治疗疾病的同时也会带来严重的并发症,如眼内炎、眼压升高、玻璃体积血等。因此,眼科医生需要更清楚地了解与这些药物相关的眼部潜在不良反应。该文综述了抗VEGF药物在眼科的应用及其潜在的不良反应,眼科医生应重点关注抗VEGF药物临床适应证及安全管理措施。
Anti-vascular endothelial growth factor(VEGF)drugs belong to biological agents,which are any pharmaceutical products containing biotechnology-derived proteins as active substances.With the increasing research and development of anti-VEGF drugs,they have achieved significant efficacy in breaking the pathophysiological process of the disease and further inhibiting the progress of the disease.At present,anti-VEGF drugs have become the main means of treating many retinal diseases in the eye,but they also bring serious complications,such as endophthalmitis,elevated intraocular pressure,vitreous hemorrhage and so on.Therefore,ophthalmologists need to have a clearer understanding of the potential ocular adverse reactions associated with these drugs.This article reviewed the application of anti-VEGF drugs in the eyes and their potential adverse reactions.Ophthalmologists should focus on the clinical indications and safety management measures of anti-VEGF drugs.
作者
刘玉秀(综述)
丁琳(审校)
LIU Yuxiu;DING Lin(Department of Ophthalmology,the People′s Hospital of Baoji City,Baoji,Shaanxi 721000,China;Department of Ophthalmology,People′s Hospital of Xinjiang Uygur Autonomous Region,Urumqi,Xinjiang 830001,China)
出处
《现代医药卫生》
2023年第21期3725-3729,3735,共6页
Journal of Modern Medicine & Health
基金
新疆维吾尔自治区科技支疆项目(2020E02127)
新疆维吾尔自治区区域协同创新专项—科技援疆计划项目(2022E02113)。
关键词
抗血管内皮生长因子药物
眼科
治疗
药物相关性副作用和不良反应
安全
综述
Anti-vascular endothelial growth factor drugs
Ophthalmology
Therapy
Drug-related side effects and adverse reactions
Safety
Review
